---
title: "Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285373390.md"
description: "Needham's Ami Fadia has reaffirmed a Buy rating on Bicycle Therapeutics (BCYC) with a price target of $15.00. Fadia, who specializes in the Healthcare sector, has an average return of 30.8% and a 56.80% success rate on stock recommendations. Additionally, TD Cowen's Tara Bancroft also rated BCYC as a Buy, while Truist Financial maintained a Hold rating on the stock."
datetime: "2026-05-06T12:03:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285373390.md)
  - [en](https://longbridge.com/en/news/285373390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285373390.md)
---

# Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)

In a report released today, Ami Fadia from Needham maintained a Buy rating on Bicycle Therapeutics, with a price target of $15.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Fadia covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Neurocrine, and Bicycle Therapeutics. According to TipRanks, Fadia has an average return of 30.8% and a 56.80% success rate on recommended stocks.

In addition to Needham, Bicycle Therapeutics also received a Buy from TD Cowen’s Tara Bancroft in a report issued on April 30. However, on May 1, Truist Financial maintained a Hold rating on Bicycle Therapeutics (NASDAQ: BCYC).

### Related Stocks

- [BCYC.US](https://longbridge.com/en/quote/BCYC.US.md)

## Related News & Research

- [Bicycle Therapeutics (NASDAQ:BCYC) Issues Quarterly Earnings Results](https://longbridge.com/en/news/279422088.md)
- [Why Needham Analysts Think Cerebras Stock Can Gain Another 25% After Historic IPO](https://longbridge.com/en/news/289219447.md)
- [As tech stocks slide, the healthcare sector shines. Why some experts say they like this defensive play](https://longbridge.com/en/news/289242691.md)
- [Evolus (EOLS) Receives a Buy from Mizuho Securities](https://longbridge.com/en/news/289108379.md)
- [CICC Keeps Their Buy Rating on ZJLD Group, Inc. (6979)](https://longbridge.com/en/news/288951475.md)